Sirio Pharma

Sirio Pharma announced on October 8 that the company and its subsidiaries obtained 4 invention patent certificates, 4 health food registration certificates, and 4 health food filing certificates in the third quarter of 2026. As of September 30, the company and its subsidiaries held a total of 212 patents, of which 123 are invention patents. The newly added invention patents include Lactiplantibacillus plantarum SP055 and its postbiotics, compositions and their preparation methods and applications, and high-stability emulsions and their preparation methods, all originally obtained by the company. During the same period, the company and its subsidiaries held a total of 115 health food registration certificates and 345 health food filing certificates. Newly added registration certificates in the third quarter include Yueding bilberry lutein carotene soft capsules and Tiancan glucosamine chondroitin sodium hyaluronate calcium soft capsules. In the first half of 2026, Sirio Pharma achieved revenue of 2.052 billion yuan and net profit attributable to the parent company of 153 million yuan.

Recently, multiple A-share listed companies have announced receipt of US tariff refunds. Hanshow Technology's wholly-owned subsidiary in the United States has cumulatively received US tariff and interest refunds totaling 23.1064 million US dollars, equivalent to approximately 157 million yuan. After withholding, the impact on the company's 2026 net profit is approximately 71.1716 million yuan, accounting for 15.75% of the most recent audited net profit. Leyard's consolidated subsidiaries have cumulatively received US tariff and interest refunds totaling 16.5598 million US dollars, equivalent to approximately 112 million yuan. The specific impact on 2026 performance remains to be confirmed. Sirio Pharma's overseas subsidiaries have cumulatively received tariff and interest refunds totaling 11.7029 million US dollars, equivalent to approximately 79.4436 million yuan. Rongjie Health's controlled subsidiaries have cumulatively received 7.252 million US dollars, with an expected impact on the company's net profit attributable to the parent of 17.9599 million yuan, accounting for 24% of the most recent audited net profit. Shanghai Jahwa's wholly-owned overseas subsidiary has cumulatively received tariff and interest refunds of 4.6636 million US dollars, equivalent to approximately 32.322 million yuan, accounting for 12.08% of the company's most recent audited net profit. CFMOTO's wholly-owned subsidiary has cumulatively received US tariff and interest refunds of 38.6079 million US dollars, equivalent to 262 million yuan, with an expected impact on 2026 net profit of approximately 183 million yuan, accounting for 10.95% of the most recent audited net profit. Healthcare Co., Ltd.'s consolidated subsidiaries have cumulatively received US tariff refunds of 2.1324 million US dollars, equivalent to approximately 14.4764 million yuan, to be included in 2026 current profit or loss.

Sirio Pharma announced that its wholly-owned overseas subsidiary SN and controlled subsidiary SNC recently received a refund from US Customs and Border Protection, after the US Supreme Court ruled that the reciprocal tariffs imposed under IEEPA lacked statutory authority and the collected tariffs must be returned. To date, the cumulative refund of tariffs and interest totals 11.7029 million US dollars, equivalent to about 79.4436 million yuan. This refund does not require retrospective adjustment of prior financial statements. Part of the amount needs to be allocated through negotiation with customers, and the specific impact is yet to be confirmed.